Inventiva (IVA) has released an update. Inventiva has announced a positive recommendation from the Data Monitoring Committee for its NATiV3 Phase 3 clinical trial of lanifibranor, highlighting the ...
The DMC review supports the continuation of the NATiV3 clinical trial without modification to the current trial protocol. This positive recommendation confirms the good safety and tolerability profile ...
This positive recommendation confirms the good safety and tolerability profile of lanifibranor. Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to ...
This positive recommendation confirms the good safety and tolerability profile of lanifibranor. About lanifibranor Lanifibranor, Inventiva’s lead product candidate, is an orally-available small ...